Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01031459 · ClinicalTrials.gov registry record

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

A clinical trial of Multiple Sclerosis, sponsored by Bayer.

Completed
Registry status
176
Enrollment target
10
Study locations

NCT01031459: Completed study of Multiple Sclerosis, sponsored by Bayer.

NCT01031459 is a study of Multiple Sclerosis that has completed, run by Bayer. The registered enrollment target is 176 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (70% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01031459, a study of Multiple Sclerosis, has completed, sponsored by Bayer.

COMPLETED
Registry status
176 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include: 1. Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related mortality 2. EDSS (Expanded Disability Status Scale) 3. Cognition 4. Resource use 5. SPMS (Secondary Progressive Multiple Sclerosis) status 6. Employment history

Conditions Studied

Interventions

  • DRUG Betaseron (Interferon beta-1b, BAY86-5046)

Study Locations (10)

Quebec

  • - Montreal
  • - Montreal

Alabama

  • - Birmingham

Arizona

  • - Tucson

California

  • - San Francisco

Illinois

  • - Chicago

Maryland

  • - Baltimore

Pennsylvania

  • - Philadelphia

British Columbia

  • - Vancouver

Trial Details

FieldValue
Enrollment Target 176 participants
Start Date 2010-01
Est. Completion 2010-12
Bayer

591 total trials

What the finished NCT01031459 record still lists

NCT01031459 is an observational study that tracks outcomes without assigning an intervention. The registered 176 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (70% lower).

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Betaseron (Interferon beta-1b, BAY86-5046) is the first listed.

NCT01031459 lists 10 locations in 9 states (Quebec, Alabama, Arizona).

Frequently Asked Questions

What is clinical trial NCT01031459 about?

NCT01031459 is a clinical study titled "Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.". The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include: 1. Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related ...

What is the current status of trial NCT01031459?

This trial is currently completed. The enrollment target is 176 participants. The study started on 2010-01. Estimated completion is 2010-12.

What conditions does trial NCT01031459 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

What interventions are being tested in trial NCT01031459?

The interventions under investigation include: Betaseron (Interferon beta-1b, BAY86-5046) (DRUG).

Who is sponsoring clinical trial NCT01031459?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01031459 being conducted?

This trial has 10 study locations across Alabama, Arizona, California, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01031459's enrollment target sits among peer trials

176 85th of 315 higher than 231 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03304821 · 176 participants · Phase 2

    Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease

  • NCT03447938 · 176 participants · NA

    The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

  • NCT03824145 · 176 participants · NA

    Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer

  • NCT04177914 · 176 participants · Phase 3

    HCRN Endoscopic Versus Shunt Treatment of Hydrocephalus in Infants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01031459, the US trial registry maintained by the National Library of Medicine. NCT01031459 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.